| Theravance Reports Third Quarter 2011 Financial Results - MarketWatch (press release) |
|
|
MarketWatch (press release) New onset or worsening renal impairment occurred in patients who received VIBATIV(R). Renal adverse events were more likely to occur in patients with baseline comorbidities known to predispose patients to kidney dysfunction and in patients who received |